HDL-cholesterol and future risk of venous thromboembolism: The Tromsø Study

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 8, 2009, Pages 1428-1430

  Brækkan, Sigrid Kufaas ^a   Borch, K H ^a   Mathiesen, E B ^a   Njolstad I ^a   Hansen, J B ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

CHOLESTEROL, HDL; FEMALE; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; RISK; SEX FACTORS; VENOUS THROMBOEMBOLISM;

EID: 67949094409     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03481.x     Document Type: Article

References (17)

1. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008; 117: 93-102.
2. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
3. Rosenson RS. Low HDL-C: A secondary target of dyslipidemia therapy. Am J Med 2005; 118: 1067-77.
4. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5.
5. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-9.
6. Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008; 112: 2675-80.
7. Everett BM, Glynn RJ, Buring JE, Ridker PM. Lipid biomarkers, hormone therapy, and the risk of venous thromboembolism in women. J Thromb Haemost 2009; 7: 588-96.
8. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: The Tromso study. J Thromb Haemost 2008; 6: 1851-7.
9. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-42.
10. Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 2005; 93: 488-93.
11. Mainous AG III, Wells BJ, Everett CJ, Gill JM, King DE. Association of ferritin and lipids with C-reactive protein. Am J Cardiol 2004; 93: 559-62.
12. Brugada R, Wenger NK, Jacobson TA, Clark WS, Cotsonis G, Iglesias A. Changes in plasma cholesterol levels after hospitalization for acute coronary events. Cardiology 1996; 87: 194-9.
13. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-5.
14. McColl MD, Sattar N, Ellison J, Tait RC, Walker ID, Packard CJ, Greer IA. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 225-9.
15. Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR, Venta Obaya R, Macias-Robles MD, Gonzalez-Franco A, Arias Garcia MA. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003; 88: 1035-43.
16. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-9.
17. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: Prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004; 104: 3046-51.